Genzyme, a Sanofi Company

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 4 drugs with upcoming expirations

Pipeline

Pipeline Snapshot

By Phase

1 drugs in development

Preclinical1

By Therapeutic Area

top 1

Neurology

1100%

R&D Momentum

27/100

Pipeline Velocity

0/100

Trial Completion Rate

N/A

Pipeline Concentration

100/100

Pipeline Freshness

0/100

Activity

Recent Activity

Last 14 days

Jul 11, 2026

Active, not recruiting

A 4-part, Open-label, Multicenter, Multinational Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamic, and Exploratory Efficacy of Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy Extension

Earlier

Jun 24, 2026TrialFabry Disease Registry Protocol

Jun 24, 2026TrialPompe Disease Registry

Jun 24, 2026TrialATLAS-PEDS: An Open-label, Multinational Study of Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B

Aug 29, 2025FDAWayrilz — WAYRILZ

Mar 28, 2025FDAQfitlia — QFITLIA

Aug 31, 2022FDAXENPOZYME — XENPOZYME

Feb 6, 2019FDACABLIVI — CABLIVI

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

11 patent groups across drugs · Source: FDA Orange Book

DrugExpires

CerdelgaJun 26, 2026 CaprelsaAug 8, 2028 CerdelgaNov 24, 2030 CerdelgaJan 31, 2031 CerdelgaJun 5, 2032 Wayrilz4 patentsMar 1, 2033 Qfitlia2 patentsMar 15, 2033 QfitliaDec 7, 2036

3 more

CerdelgaDec 13, 2038 WayrilzOct 13, 2040 WayrilzFeb 20, 2041

Pipeline

Drug Pipeline

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Neurology

Gaucher Disease Type 1

XENPOZYME

Neurology

Gaucher Disease Type 1

XENPOZYMEPreclinical

Regulatory

Regulatory Timeline

19941 event

FDAMay 23

CEREZYME — CEREZYME

Application BLA020367 (BLA)

19982 events

FDANov 30

THYROGEN — THYROGEN

Application BLA020898 (BLA)

FDAOct 30

Renagel — RENAGEL

Application NDA020926 (NDA)

20001 event

FDAJul 12

Renagel — RENAGEL

Application NDA021179 (NDA)

20011 event

FDAMay 7

Campath — CAMPATH

Application BLA103948 (BLA)

20031 event

FDAApr 30

ALDURAZYME — ALDURAZYME

Application BLA125058 (BLA)

20041 event

FDADec 28

Clolar — CLOLAR

Application NDA021673 (NDA)

20081 event

FDADec 15

Mozobil — MOZOBIL

Application NDA022311 (NDA)

20101 event

FDAMay 24

Lumizyme — LUMIZYME

Application BLA125291 (BLA)

20111 event

FDAApr 6

Caprelsa — CAPRELSA

Application NDA022405 (NDA)

20141 event

FDAAug 19

Cerdelga — CERDELGA

Application NDA205494 (NDA)

20191 event

FDAFeb 6

CABLIVI — CABLIVI

Application BLA761112 (BLA)

20221 event

FDAAug 31

XENPOZYME — XENPOZYME

Application BLA761261 (BLA)

20252 events

FDAAug 29

Wayrilz — WAYRILZ

Application NDA219685 (NDA)

FDAMar 28

Qfitlia — QFITLIA

Application NDA219019 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)